169 related articles for article (PubMed ID: 20819841)
21. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
He W; Liu J; Binkowitz B; Quan H
Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
[TBL] [Abstract][Full Text] [Related]
22. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
Morita S
Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
[TBL] [Abstract][Full Text] [Related]
23. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
Resche-Rigon M; Zohar S; Chevret S
Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
[TBL] [Abstract][Full Text] [Related]
24. Sequential designs for logistic phase I clinical trials.
Liu G; Rosenberger WF; Haines LM
J Biopharm Stat; 2006; 16(5):605-21. PubMed ID: 17037261
[TBL] [Abstract][Full Text] [Related]
25. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
Bekele BN; Shen Y
Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
[TBL] [Abstract][Full Text] [Related]
26. Two-dimensional dose finding in discrete dose space.
Wang K; Ivanova A
Biometrics; 2005 Mar; 61(1):217-22. PubMed ID: 15737096
[TBL] [Abstract][Full Text] [Related]
27. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial design for drug combinations with Bayesian model averaging.
Jin IH; Huo L; Yin G; Yuan Y
Pharm Stat; 2015; 14(2):108-19. PubMed ID: 25641851
[TBL] [Abstract][Full Text] [Related]
29. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
Tighiouart M; Rogatko A; Babb JS
Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
[TBL] [Abstract][Full Text] [Related]
30. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
Ivanova A; Wang K
Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
[TBL] [Abstract][Full Text] [Related]
31. An optimization algorithm for designing phase I cancer clinical trials.
Jiang H; Liu Y; Su Z
Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
[TBL] [Abstract][Full Text] [Related]
32. Adaptive dose modification for phase I clinical trials.
Chu Y; Pan H; Yuan Y
Stat Med; 2016 Sep; 35(20):3497-508. PubMed ID: 27027650
[TBL] [Abstract][Full Text] [Related]
33. An Adaptive Staggered Dose Design for a Normal Endpoint.
Wu J; Menon S; Chang M
J Biopharm Stat; 2015; 25(4):731-56. PubMed ID: 24904986
[TBL] [Abstract][Full Text] [Related]
34. Dose escalation trial designs based on a molecularly targeted endpoint.
Hunsberger S; Rubinstein LV; Dancey J; Korn EL
Stat Med; 2005 Jul; 24(14):2171-81. PubMed ID: 15909289
[TBL] [Abstract][Full Text] [Related]
35. Adaptive designs for dose-finding studies based on sigmoid Emax model.
Dragalin V; Hsuan F; Padmanabhan SK
J Biopharm Stat; 2007; 17(6):1051-70. PubMed ID: 18027216
[TBL] [Abstract][Full Text] [Related]
36. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.
Potter DM
J Biopharm Stat; 2006; 16(5):579-604. PubMed ID: 17037260
[TBL] [Abstract][Full Text] [Related]
37. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
38. Improved up-and-down designs for phase I trials.
Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD
Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752
[TBL] [Abstract][Full Text] [Related]
39. Designs for phase I clinical trials with multiple courses of subjects at different doses.
Fan SK; Wang YG
Biometrics; 2007 Sep; 63(3):856-64. PubMed ID: 17403103
[TBL] [Abstract][Full Text] [Related]
40. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
Yin G; Li Y; Ji Y
Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]